Triple Antibiotics No Better Than Cephalosporin Alone in PPROM

This observational comparative-effectiveness study informs whether adding azithromycin and clindamycin to cephalosporin prophylaxis meaningfully improves maternal or neonatal outcomes in preterm premature rupture of membranes.

cefuroximeazithromycinclindamycincephalosporinmacrolidePPROMpreterm premature rupture of membranesbronchopulmonary dysplasiaintraventricular hemorrhageneonatal RDScohort studyantibiotic prophylaxiswomen's health Women's Health / Reproductive

Background Information

Triple therapy may lower BPD and IVH risks in PPROM.

Determining optimal antibiotic regimens for preterm premature rupture of membranes (PPROM) is crucial for improving maternal and neonatal outcomes. Triple therapy showed no significant differences in primary outcomes but suggested lower risks of bronchopulmonary dysplasia (BPD) and intraventricular hemorrhage (IVH) in exploratory analyses. Findings suggest possible benefits of triple therapy for specific conditions, though the nonrandomized design and small sample size limit generalizability. Triple therapy may reduce risks of BPD and IVH but requires further study.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Luo C, Yang C, Zhou T, Zheng P, Lin T, Deng X, Sheng C, Li Y

Citation: Luo C, Yang C, Zhou T, et al. Evaluation of Preventive Antibiotic Regimens for Preterm Premature Rupture of Membranes: Efficacy and Safety of Triple Therapy versus Cephalosporin Monotherapy. Drug design, development and therapy. 2026;20:626846. doi:10.2147/DDDT.S626846

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →